Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.

Trial Profile

Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Pulmonary embolism
  • Focus Therapeutic Use
  • Acronyms PEITHO-2
  • Most Recent Events

    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top